← Back to Clinical Trials
Recruiting Phase 4 NCT07084402

Short-term Bactericidal Effect of Contezolid in MAC-PD

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Mycobacterium Avium Complex Pulmonary Disease
Sponsor Bin Cao
Study Type INTERVENTIONAL
Phase Phase 4
Enrollment 188
Sex ALL
Min Age 18 Years
Max Age 75 Years
Start Date 2025-07-24
Completion 2027-07-24
Interventions
ContezolidAzithromcyinRifampicin (RIF)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The goal of this clinical trial is to learn if contezolid works to treat mycobacterium avium complex pulmonary disease in adults. It will also learn about the safety of contezolid. The main questions it aims to answer are: Does adding contezolid to standard regimen further decrease the bacterial load in patients' sputum compared with current standard regimen? What medical problems do participants have when taking contezolid along with standard regimen? Researchers will compare standard regimen plus contezolid to standard regimen alone to see if contezolid helps further lower the count of bacteria in patients' sputum. Participants will: Take contezolid and standard regimen (azithromycin, ethambutol and rifampicin) or standard regimen only for 6 months, contezolid is administered every day while other drugs are taken 3 times a week Visit the clinic once every 1 month for checkups and tests.

Eligibility Criteria

Inclusion Criteria: 1. Patients voluntarily participate in this study and sign the Informed Consent Form. 2. Age ≥ 18 years and ≤75 years; gender unrestricted. 3. Confirmed diagnosis of MAC pulmonary disease per ATS/IDSA 2020 guidelines or Chinese Guidelines for Diagnosis and Treatment of Nontuberculous Mycobacterial Diseases (2020 edition), with imaging features consistent with nodular bronchiectatic type. 4. No prior anti-MAC treatment within the 3 months preceding screening. 5. For premenopausal women of childbearing potential who are not surgically sterile: Must use a medically accepted contraceptive method (e.g., intrauterine device, hormonal contraception, or condom) during the study period and for 3 months following the last dose of investigational treatment. Serum or urine human chorionic gonadotropin (hCG) test must be negative within 72 hours prior to enrollment. Must not be breastfeeding. Male patients with partners of childbearing potential must use effective contraception

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}